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OBJECTIVEdActivating mutations in the KCNJ11 gene, encoding the Kir6.2 subunit of the
KATP channel, result in permanent neonatal diabetes mellitus. They also may cause neurologic
symptoms such as mental retardation and motor problems (iDEND syndrome) and epilepsy
(DEND syndrome). Sulphonylurea (SU) treatment is reported to alleviate both the neurologic
symptoms and diabetes in such cases. The study aimed to establish themagnitude and functional
basis of the effect of SUs on the neurologic phenotype in children with iDEND using neuro-
imaging before and after insulin replacement with glibenclamide.
RESEARCHDESIGNANDMETHODSdTo localize andquantify the effect of glibenclamide
administration, we performed single-photon emission computed tomography in seven patients
with different mutations in KCNJ11. In five patients, measurements before and after initiation of
SU treatment were performed.
RESULTSdSignificant changes in single-photon emission computed tomography signal inten-
sity after transfer to SU therapy were restricted to the cerebellum, consistent with previous data
showing high Kir6.2 expression in this brain region. Cerebellar perfusion improved for both left (P =
0.006) and right (P = 0.01) hemispheres,with themean improvement being 26.76 7.1% (n = 5).No
patients showed deterioration of cerebellar perfusion on SU therapy. Electrophysiological studies
revealed a good correlation between the magnitude of KATP channel dysfunction and the clinical
phenotype; mutant channels with the greatest reduction in adenosine 59-triphosphate inhibition
were associated with the most severe neurologic symptoms.
CONCLUSIONSdWe conclude it is likely that at least some of the beneficial effects of SU
treatment on neurodevelopment in iDEND patients result from improved cerebellar perfusion.
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Approximately 50% of cases of per-manent neonatal diabetes mellitusare caused by mutations in the
genes encoding either the pore-forming
(Kir6.2, KCNJ11) or regulatory (SUR1,
ABCC8) subunits of the ATP-sensitive
K+ (KATP) channel (1). In some patients
with these mutations, neurologic symp-
toms such as mental retardation,
impaired motor development, and
hypotonia coexist with neonatal diabetes
(iDEND syndrome); if epilepsy is also
present, then the condition is called
DEND syndrome (2). Previous studies
have shown that it is possible to alleviate
diabetes and some of the neurologic
symptoms by substituting insulin therapy
with orally ingested sulphonylurea (SU)
drugs (3). In one patient, the improve-
ment in neurologic function was associ-
ated with enhanced perfusion of the
brain, particularly of the cerebellum, as
measured by single-photon emission
computed tomography (SPECT). To de-
termine if this effect is common to pa-
tients treated with SU, we performed
SPECT in patients with different muta-
tions in KCNJ11 and varying clinical phe-
notypes.
RESEARCH DESIGN AND
METHODSdThe Ethics Committee of
the Medical University of Lodz approved
the project. Parents of participants gave
written informed consent for participa-
tion of their children in the study.
The study group consisted of seven
patients (four boys and three girls) with
gain-of-functionmutations of theKCNJ11
gene who were recruited to the Polish
Registry of Monogenic Diabetes (The
TEAM project). Their clinical characteris-
tics are presented in Table 1. All patients
transferred successfully to SU and showed
improved blood glucose levels (4). The age
of the patients at the time of transfer ranged
from 5 to 21 years.
Mental and motor development
Rudimentary neurologic testing was per-
formed for all patients before and after
introduction of SU therapy, as described
previously (3). Briefly, an assessment of
mental and motor function was per-
formed using medical records of develop-
mental milestones during infancy and
up to the age of 2 years. The Wechsler
Preschool and Primary Scale of Intelli-
gence–Revised (WPPSI-R) was used to as-
sess mental development. Attention deficit
hyperactivity disorder was diagnosed
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according to criteria provided in the
fourth edition of the American Psychiatric
Association’s Diagnostic and Statistical
Manual. Electroencephalography (EEG)
was performed using 32-channel digital
EEG equipment (ELMIKO, Warsaw, Po-
land), but only before SU therapy. For re-
cording, viewing, analysis, and archiving
of EEG records, ELMIKO DigiTrack (EL-
MIKO, Warsaw, Poland) software was ap-
plied. The records were analyzed by a
neurophysiologist and verified by the con-
sultant in pediatric neurology.
SPECT studies
Imaging studies were performed twice
(before and 6 months after switching
from insulin to SU) in five individuals
with the following mutations: H46 L (3),
R201H, R50Q, G53D, and V59M. One
patient with a G53D mutation was exam-
ined only before transfer to SU and the
patient with an E229 K mutation was
only available after transfer.
SPECT studies of brain perfusion
were performed according to the Euro-
pean Association of Nuclear Medicine
procedure guidelines for brain perfusion
SPECT using technetium 99m (99mTc)-
labeled radiopharmaceuticals version 2 (5)
after intravenous injection of 99mTc ethyl
cysteine dimer under resting conditions.
SPECT scanning was performed using a
dual-head g camera Infinia Hawkeye (GE
Medical System) with a dedicated com-
puter workstation (Xeleris). Examina-
tions were assessed by two independent
experienced nuclear medicine reviewers
(M.G., M.Bi.) in triplicate to minimize the
risk of intraobserver and interobserver
bias. The NeuroGam, an application li-
censed by Segami Corporation, was
used for qualitative and quantitative
voxel analyses of brain perfusion in re-
spective regions of interest. These were
performed separately for left and right
hemispheres. The serum glucose level
was measured before and after SPECT
examination (range, 4.9–5.9 mmol/L).
For all SPECT examinations, the patients
were administered total intravenous an-
esthesia using ketamine. This was dic-
tated by the fact that four of the patients
were younger than age 9 years, patient
Pol32 had severe mental retardation,
and patient Pol23 had attention deficit
hyperactivity disorder diagnosed. There-
fore, to reduce any variability attributable
to patient anxiety or lack of cooperation,
we obtained Bioethics Committee approval
to perform these studies under short-term
intravenous general anesthesia, includingT
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Neurologic effects of pharmacogenetics in iDEND syndrome
approval for collaborative patients older
than 9 years of age to unify conditions
of the study. Both examinations were per-
formed;1 h after intravenous injection of
99mTc-ethyl cysteine dimer under resting
conditions. To eliminate possible anatom-
ical variability, we performed simulta-
neous magnetic resonance imaging
examination and SPECT/magnetic reso-
nance imaging digital fusion of images.
We compared individual density counts
for all regions of interest and, to make
our results comparable with the reference
range in children (6), we computed cerebro-
cerebellar indexes by dividing density
counts of particular regions by those of
the cerebellum.
Comparisons were made with the
Mann-Whitney U test with a Benjamini-
Hochberg procedure used for false dis-
covery rate computation to correct for
multiple hypothesis testing.
Electrophysiological studies
Human Kir6.2 (Genbank NM000525;
E23 and I337) and rat SUR1 (Genbank
L40624) were used. Site-directed muta-
genesis, synthesis of capped mRNA, and
preparation and culture of Xenopus laevis
oocytes were performed as previously re-
ported (7). Oocytes were coinjected with
;4 ng of SUR1 mRNA and ;0.8 ng of
wild-type (WT) or mutant Kir6.2-G53D
mRNA and studied 1–4 days after injection.
Whole-cell (WC) currents were re-
corded using a two-electrode voltage-
clamp in response to voltage steps of 6
20 mV from a holding potential of –10
mV in a solution containing the following
(mmol/L): 90 KCl, 1 MgCl2, 1.8 CaCl2,
and 5 HEPES (pH 7.4 with KOH). Meta-
bolic inhibition was induced by 3mmol/L
Na-azide. Tolbutamide (0.5 mmol/L) was
used to block KATP channels.
ATP sensitivity was measured in in-
side-out patches at 260 mV. The pipette
(external) solution contained the follow-
ing (mmol/L): 140 KCl, 1.2 MgCl2, 2.6
CaCl2, and 10 HEPES (pH 7.4 with
KOH). The intracellular solution con-
tained the following (mmol/L): 107 KCl,
11 EGTA, 2 MgCl2, 1 CaCl2, 10 HEPES
(pH 7.2 with KOH), and MgATP as indi-
cated. Control solutions were alternated
with test (ATP-containing) solutions and
current (I) is expressed as a fraction of
the mean of that in control solution (Ic)
before and after ATP application. ATP
concentration-response curves were fit
to the following: I/Ic = 1/[1+[(ATP)/IC50]
h], where [ATP] is the ATP concentration,
IC50 is the ATP concentration at which
Figure 1dA: Representative SPECT scans of brain perfusion paired during insulin and SU
therapy for the patient with a V59M substitution in Kir6.2 (NeuroGam software). B: Hierarchical
clustering heat map for average signal intensity in the indicated brain regions for patients with the
specified mutations before and after transfer to SU therapy. Brighter red represents increased
99mTc-ethyl cysteine dimer uptake corresponding to augmented perfusion. Pearson correlation
coefficients were used as distance measurements in this analysis and are shown as a dendrogram
on the left side of the heatmap.C: Mean SPECT signal intensity in the left and right hemispheres of
the cerebellum before and after initiation of SU treatment.
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inhibition is half maximal, and h is the
slope factor.
RESULTS
Clinical evaluation
All patients had KCNJ11 mutations, with
four patients being classified as having
iDEND and three as having permanent
neonatal diabetes mellitus. All patients
had normal EEG recordings. None of
the permanent neonatal diabetes mellitus
patients had neurologic features. Among
iDEND children, one patient (Pol23) had
attention deficit hyperactivity disorder
and mild mental retardation diagnosed,
one (Pol32) had moderate mental retar-
dation and severe motor disability, and
two patients had only mild mental retar-
dation. Only one (Pol23) showed signifi-
cant improvement in mental and motor
function with SU therapy. This patient
has been described previously (3).
SPECT studies
Figure 1A shows representative SPECT
scans from the same iDEND patient, first
when treated with insulin and then sub-
sequently treated with SU.
Average scores of signal intensity for
respective brain regions of interest in all
tested patients were computed and sub-
jected to hierarchical clustering using
Spearman r coefficient as a distance mea-
sure. Changes in regional perfusion are
shown in Fig. 1A–C and in the Supple-
mentary Table 1. Significant changes in
signal intensity after transfer to SU ther-
apy were restricted to the cerebellum. A
marked improvement in paired observa-
tion comparisons for cerebellar perfusion
was observed in all cases except for the
patient with the R201H mutation (8).
The signal intensity was significantly
higher for both the left (P = 0.006; false
discovery rate, 0.13) and right (P = 0.01;
false discovery rate, 0.13) cerebral hemi-
sphere after introduction of SU treatment
(Fig. 1A–C). The mean improvement was
26.7 6 7.14% (n = 5). No patients
showed deterioration of cerebellar perfu-
sion with SU therapy. The mean signal
change in all other regions did not exceed
the range of21.5 to 4.5% in signal inten-
sity variation (Supplementary Table 1),
which was within the range of intraindi-
vidual variability (5.96 and 7.20%,
depending on the assessing radiologist)
and the range of assessor-dependent var-
iability (4.55%). As scores for the cerebel-
lum increased because of SU treatment, the
cerebro-cerebellar indexes proportionally
Figure 2dA: Mean6 SEM for steady-state WC KATP currents evoked by a voltage step from –10
to –30 mV before (resting) and after application of 3 mmol/L Na-azide, and after application of
0.5 mmol/L tolbutamide (Tolb) for oocytes injected with Kir6.2 (white; n = 12) or a 1:1 mixture of
Kir6.2 and Kir6.2-G53D (black; n = 24) mRNA, plus SUR1mRNA. B: Mean6 SEM forWC KATP
currents evoked by a voltage step from –10 to –30 mV under resting conditions and after ap-
plication of 0.5 mmol/L Tolb for oocytes injected with Kir6.2 (white; n = 12) or a 1:1 mixture of
Kir6.2 and Kir6.2-G53D (black; n = 24) mRNA, plus SUR1 mRNA. Currents are expressed as
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decreased, reaching normal reference
values for children 4–15 years of age (Sup-
plementary Table 2).
Electrophysiological parameter
correlations
We also compared the effect of the pa-
tients’ mutations on KATP channel inhibi-
tion by ATP and metabolism. Because all
patients are heterozygotes, we simulated
the heterozygous state by coexpressing
SUR1 with a 1:1 mixture of WT and mu-
tant Kir6.2. For each mutation, we mea-
sured the magnitude of the WC KATP
current at rest after activation by the met-
abolic inhibitor azide and inhibition by
the SU tolbutamide. We also measured
the ATP concentration–inhibition rela-
tionship. Figure 2A–C shows data ob-
tained for the Kir6.2-G53D mutation
and Table 2 gives the mean data for WT
channels and all mutant channels. All mu-
tations increased the IC50 for ATP inhibi-
tion and the current magnitude in the
presence of 3 mmol/L MgATP (a physio-
logical concentration); the greatest reduc-
tion in ATP block was found for the
iDEND mutation H46L. The magnitude
of the WC current in the absence of met-
abolic inhibition correlated with the clin-
ical phenotype; the largest currents were
found for the most clinically severe muta-
tions. These mutations also showed a
lower degree of tolbutamide block.
CONCLUSIONSdIt is clear that the
mutations that cause the most severe
neurologic phenotype are those that
show the largest resting WC KATP cur-
rents. In order of functional severity, the
mutations were as follows: H46L.G53D
; V59M. R50Q; R210H; E229 K.
WT. Patients with least severe mutations
(R50Q, R201H, and E229 K) did not
show neurologic symptoms.
Themost pronounced changes in brain
blood flow resulting from transfer from
insulin to SU treatment were observed in
the cerebellum. All patients (with the ex-
ception of the one carrying the R210H
mutation) showed an increase in cerebel-
lar perfusion. The R201H patient had
the highest cerebellar perfusion initially
and this did not change after transfer to
glibenclamide; this pattern might be ex-
pected because this mutation is not a
severe one. The G53D, V59M, and H46 L
mutations all cause neurologic problems,
and patients with these mutations had a
lower initial cerebellar perfusion with in-
sulin, which increased to approximately
the same level as for the R201H patient
when administered SU. This is consistent
with the fact that they cause a more severe
phenotype and therefore might be expec-
ted to cause worse perfusion with insulin
therapy than the R201H mutation.
The patient with R50Q mutation
showed unexpected results. Despite the
absence of neurologic symptoms and
only a moderate impairment of channel
function, the SPECT signal intensity with
insulin therapy was the lowest and it
showed the largest increase. It is possible
that other confounding factors may
influence cerebellar perfusion in this in-
dividual, but this remains to be deter-
mined.
In pancreatic b cells, an increased
KATP current would lead tomembrane hy-
perpolarization and inhibition of insulin
secretion. In neurons, it is expected to
result in reduced electrical activity. All
currents were strongly blocked by tolbu-
tamide, suggesting that if SU is able to
cross the blood–brain barrier, then it
should close mutant KATP channels. The
large changes in cerebellar perfusion are
consistent with the fact that Kir6.2 is
strongly expressed within the cerebellum
(9). Furthermore, when the V59M gain-
of-function mutation was selectively
expressed in neurones in a genetically
modified mouse model, the electrical ac-
tivity of cerebellar Purkinje cells was im-
paired (10). These mice also showed
motor problems, including impaired bal-
ance and coordination, as predicted if cer-
ebellar function was impaired. Purkinje
cell electrical activity in brain slices from
these mice was fully restored by a high
dose of the SU tolbutamide (10).
A key question is the extent towhich SU
is able to target brain neurons in vivo. The
increase in SPECT signal that we observed
in patients treated with glibenclamide sug-
gests the drug may be able to cross the
blood–brain barrier, at least to some ex-
tent. We propose that glibenclamide
closes KATP channels in cerebellar neu-
rons, thereby stimulating electrical activ-
ity, which in turn leads to an increase in
blood flow and SPECT signal intensity.
Neurologic improvement observed in
patients with KCNJ11 mutations treated
with SUmanifests as improvedmotor func-
tion (11–13) and, in some cases, amelio-
rated cognitive function (3,14). Our
finding of increased cerebellar perfusion
in all patients after SU therapy could ex-
plain the previously reported improvements
a percentage of the maximum current evoked by application of 3 mmol/L azide. C: Mean6 SEM
for relationships between [ATP] and KATP current (I), expressed relative to that in the absence of
nucleotide (Ic), for Kir6.2/SUR1 (WT, open circles, n = 16), and hetKir6.2-G53D/SUR1
(hetG53D, closed circles; n = 10) channels in the presence of Mg2+. The lines are drawn to
equation 1, with the following parameters: WT (IC50 = 25 mmol/L, h = 1.1) and hetG53D (IC50 =
83 mmol/L, h = 0.8).
Table 2dElectrophysiological data for KATP channels carrying the indicated mutation in Kir6.2 (KCNJ11) studied in the heterozygous state
Mutation
IC50 mmol/L
(MgATP)
Current at 3 mmol/L MgATP
as a percentage of that in
the absence of MgATP
Percent block of WC
current by 0.5 mmol/L
tolbutamide
Resting WC current as
a percentage of that
in 3 mmol/L azide
Fold increase in
resting WC current
compared with WT Reference
H46L 544 6 157 17 6 3 87 6 3 55 18 Mlynarski (3)
R50Q 128 6 16 8.2 6 0.8 89 6 4 7 2 Shimomura (17)
V59M 44 6 7 13 81 6 1 17 6 7 5 Proks (18)
R201H 143 6 25 8 As WT 8.5 3 Proks (18)
E229K 82 6 13 3.7 6 1.5 95 3.5 d Girard (16)
G53D 102 6 22 (n = 10) 5.7 6 1.3 (n = 10) 81 6 3 (n = 24) 19 6 2 (n = 24) 6 This study
WT 29 6 5 (n = 16) 1.1 6 0.3 (n = 6) 97 6 1 (n = 12) 3 6 1 (n = 12) d This study
Data on previously reported mutations (3,16–18) are provided for comparative purposes with experimental data on G53D and WT channels. The IC50 and current
remaining at 3 mmol/L MgATP were measured in inside-out patches. Other measurements are from WC currents. IC50, half-maximal inhibitory concentration.
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of motor function in glibenclamide-
treated patients (3,11–14). Because all
patients were walking before insulin re-
placement and detailed neurologic test-
ing was not performed before transfer,
we could not quantify the extent of mo-
tor improvement. Despite the observed
benefits, it should be noted that the
long-term clinical consequences of this
therapy remain unknown and the pa-
tients will require further follow-up
evaluation.
Because SPECT examinations were
performed under short-term anesthesia
with ketamine, there was a slight risk that
this drug affected the results of the study.
However, because we focused on an in-
dividual patient’s change in perfusion and
the same kind of anesthesia was used on
both occasions, we think it is unlikely that
ketamine would influence the observed
amelioration in cerebellum perfusion.
No data are available that would suggest
children with KCNJ11 mutations exhibit
a different reaction to ketamine than
healthy children, suggesting a disease-
specific bias also is not likely.
Although our study has several limi-
tations such as a small sample size (re-
flecting the rarity of this disease) and the
lack of objectively quantified motor per-
formance in these patients, we believe
that both the neuroimaging and electro-
physiological studies shown in this study
support the hypothesis of a cerebellum-
related effect of SU in iDEND.
In view of clinically confirmed im-
provement in neurologic function (3) and
the beneficial changes we observed in im-
aging studies, we conclude that SU treat-
ment in patients with iDEND syndrome
caused by KCNJ11 mutations may exert a
beneficial effect on the developing brain
and may improve cerebellar perfusion.
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